Rankings
▼
Calendar
AMLX Q1 2025 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMLX
Amylyx Pharmaceuticals, Inc.
$1B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
$0
Operating Income
-$38M
Net Income
-$36M
EPS (Diluted)
$-0.42
QoQ Revenue Growth
+100.0%
Cash Flow
Operating Cash Flow
-$40M
Free Cash Flow
-$40M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$220M
Total Liabilities
$18M
Stockholders' Equity
$201M
Cash & Equivalents
$60M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$89M
-100.0%
Gross Profit
$0
-$28M
+100.0%
Operating Income
-$38M
-$122M
+69.0%
Net Income
-$36M
-$119M
+69.8%
← FY 2025
All Quarters
Q2 2025 →